Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
88 hedge funds and large institutions have $314M invested in Catalyst Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 27 reducing their positions, and 13 closing their positions.
233% more capital invested
Capital invested by funds: $94.3M → $314M (+$220M)
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
12.12% more ownership
Funds ownership: 47.83% → 59.95% (+12%)
2% more funds holding
Funds holding: 86 → 88 (+2)
4% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 27
43% less call options, than puts
Call options by funds: $683K | Put options by funds: $1.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$24.9M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$5.36M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$3.2M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$2.94M |
| 5 |
HRCM
Hawk Ridge Capital Management
Los Angeles,
California
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.76M |
| 2 |
BC
Broadfin Capital
New York
|
-$1.21M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$920K |
| 4 |
DMK
David M. Knott
|
-$302K |
| 5 |
IG
ING Group
Amsterdam,
Netherlands
|
-$271K |
CPRX Hedge Fund Activity: Q1 2019 in Review
88 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2019, worth a combined $314M — up 233% from $94.3M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CPRX positions and 13 closed out — a net gain of 2 holders — while 26 added to existing stakes and 27 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $24.9M. The largest seller was Morgan Stanley, cutting an estimated $2.76M.
- 88 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2019, up from 86 in Q4 2018.
- Funds reported $314M of Catalyst Pharmaceutical stock for Q1 2019, up 233% quarter-over-quarter.
- 15 funds opened new Catalyst Pharmaceutical positions in Q1 2019 and 13 closed out, a net change of +2 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2019 was Consonance Capital Management, an estimated $24.9M added.
- The largest Catalyst Pharmaceutical seller in Q1 2019 was Morgan Stanley, an estimated $2.76M sold.
Based on aggregated 13F filings for Q1 2019.